Skip to content
Catalyst

2-hydroxy-4-methylvaleric acidWhat was measured

Measured, with no finding

79 endpoints

Show what was measuredHide what was measured
  • fat mass

    no effect

    while fat mass remained constant

    PMID 20051111 · one of two readings recorded this

  • hemoglobin

    The average value for the total subject group was 150 ± 6.4 g/l in hemoglobin and 44 ± 0.03 in hematocrit

    PMID 20051111 · one of two readings recorded this

  • 20 m sprint

    no effect

    20 m (s) | 3.02 ± 0.06 | 3.04 ± 0.11 | 2.96 ± 0.05 | 2.98 ± 0.06

    PMID 20051111 · one of two readings recorded this

  • 400 m run

    no effect

    400 m (s) | 61.3 ± 1.8 | 61.7 ± 1.6 | 60.2 ± 1.7 | 59.1 ± 0.7

    PMID 20051111 · one of two readings recorded this

  • 5-jump

    no effect

    5-jump (m) | 13.44 ± 0.71 | 13.80 ± 0.73 | 13.22 ± 0.70 | 13.63 ± 0.91

    PMID 20051111 · one of two readings recorded this

  • bench press 1RM

    no effect

    Bench press 1RM (kg) | 87.5 ± 21.0 | 87.9 ± 20.9 | 82.5 ± 13.5 | 83.3 ± 14.6

    PMID 20051111 · one of two readings recorded this

  • body composition of upper extremities

    no effect

    There were no differences between the groups in body composition of upper extremities

    PMID 20051111 · one of two readings recorded this

  • body weight

    increases, p = 0.005

    The difference between the treatments was significant in body weight (p < 0.005)

    PMID 20051111 · one of two readings recorded this

  • body weight

    Body weight was in the HICA group before and after the 4-week study period 72.6 ± 9.1 kg and 72.9 ± 8.6 kg and in the PLACEBO group 70.0 ± 5.2 kg and 70.1 ± 5.1 kg, respectively

    PMID 20051111 · one of two readings recorded this

  • body weight

    Body weight was in the HICA group before and after the 4-week study period 72.6 ± 9.1 kg and 72.9 ± 8.6 kg and in the PLACEBO group 70.0 ± 5.2 kg and 70.1 ± 5.1 kg, respectively

    PMID 20051111 · one of two readings recorded this

  • bone mass

    no effect

    Also bone mass (3.6 ± 0.1 kg) remained constant in both groups

    PMID 20051111 · one of two readings recorded this

  • countermovement jump (CMJ)

    no effect

    CMJ (m) | 43.5 ± 0.03 | 42.8 ± 0.06 | 42.3 ± 0.06 | 44.2 ± 0.05

    PMID 20051111 · one of two readings recorded this

  • dietary carbohydrate intake

    energy 11183 ± 2361 kJ, protein 119 ± 37 g, carbohydrate 341 ± 87 g, and fat 82 ± 23 g

    PMID 20051111 · one of two readings recorded this

  • dietary energy intake

    energy 11183 ± 2361 kJ, protein 119 ± 37 g, carbohydrate 341 ± 87 g, and fat 82 ± 23 g

    PMID 20051111 · one of two readings recorded this

  • dietary fat intake

    energy 11183 ± 2361 kJ, protein 119 ± 37 g, carbohydrate 341 ± 87 g, and fat 82 ± 23 g

    PMID 20051111 · one of two readings recorded this

  • dietary protein intake

    energy 11183 ± 2361 kJ, protein 119 ± 37 g, carbohydrate 341 ± 87 g, and fat 82 ± 23 g

    PMID 20051111 · one of two readings recorded this

  • full squat 1RM

    no effect

    Full squat 1RM (kg) | 120 ± 19 | 130 ± 24 | 131 ± 29 | 138 ± 16

    PMID 20051111 · one of two readings recorded this

  • hematocrit (group comparison)

    no effect

    There were no differences in hemoglobin or hematocrit between the groups of HICA and PLACEBO or between before and after measurements in each group

    PMID 20051111 · one of two readings recorded this

  • hematocrit

    The average value for the total subject group was 150 ± 6.4 g/l in hemoglobin and 44 ± 0.03 in hematocrit

    PMID 20051111 · one of two readings recorded this

  • hemoglobin (group comparison)

    no effect

    There were no differences in hemoglobin or hematocrit between the groups of HICA and PLACEBO or between before and after measurements in each group

    PMID 20051111 · one of two readings recorded this

  • lactate after 400 m run

    no effect

    lactate (mmol/l) a | 13.6 ± 1.3 | 14.5 ± 2.2 | 14.4 ± 2.8 | 14.2 ± 2.9

    PMID 20051111 · one of two readings recorded this

  • lean body mass of lower extremities, DXA regional

    increases, 400 g increase in HICA versus 150 g decrease in PLACEBO, p = 0.01

    Not recorded as a finding: Regional lean mass is a subgroup of the whole-body lean-mass node (node is whole-body FFM); no node for the lower-extremity compartment.

    The lean body mass of lower extremities increased by 400 g in the HICA group but decreased by 150 g in the PLACEBO group and the changes between the groups differed significantly (p < 0.01).

    PMID 20051111 · one of two readings recorded this

  • lean body mass of lower extremities (treatment difference)

    increases, p = 0.05

    The difference between the treatments was significant also in lean body mass of lower extremities (p < 0.05)

    PMID 20051111 · one of two readings recorded this

  • lean body mass of lower extremities

    increases, p = 0.01

    The lean body mass of lower extremities increased by 400 g in the HICA group but decreased by 150 g in the PLACEBO group and the changes between the groups differed significantly (p < 0.01)

    PMID 20051111 · one of two readings recorded this

  • matches during study

    The training amount across the study period consisted of 13 ± 3 soccer sessions, 4 ± 1 strength training sessions and 3 ± 1 matches

    PMID 20051111 · one of two readings recorded this

  • performance variables, including bench press 1RM, full squat 1RM and countermovement jump (CMJ), field tests

    no effect, no significant differences between groups in any variable

    Not recorded as a finding: The only two-sided sentence says 'any of the variables' and never names 1RM or CMJ, so no object span exists inside the quote; the figures sit in a table.

    There were no significant differences between the groups HICA and PLACEBO in any of the variables.

    PMID 20051111 · one of two readings recorded this

  • pH after 400 m run

    no effect

    pH a | 7.09 ± 0.11 | 7.17 ± 0.12 | 7.12 ± 0.12 | 7.17 ± 0.12

    PMID 20051111 · one of two readings recorded this

  • soccer sessions during study

    The training amount across the study period consisted of 13 ± 3 soccer sessions, 4 ± 1 strength training sessions and 3 ± 1 matches

    PMID 20051111 · one of two readings recorded this

  • strength endurance (row after bench press)

    no effect

    Strength endurance (reps) | 31 ± 3 | 32 ± 4 | 28 ± 2 | 31 ± 3

    PMID 20051111 · one of two readings recorded this

  • strength endurance (row after full squat)

    no effect

    Strength endurance (reps) | 31 ± 8 | 47 ± 5 | 36 ± 10 | 38 ± 11

    PMID 20051111 · one of two readings recorded this

  • strength training sessions during study

    The training amount across the study period consisted of 13 ± 3 soccer sessions, 4 ± 1 strength training sessions and 3 ± 1 matches

    PMID 20051111 · one of two readings recorded this

  • training alertness (week 1)

    no effect

    Training alertness was during every study week slightly better in the HICA group (3.6 ± 0.5; 4.2 ± 0.5; 4.1 ± 0.5; 4.3 ± 0.6) compared to the PLACEBO group (3.3 ± 0.6; 3.0 ± 0.9; 3.4 ± 1.1; 3.4 ± 0.8) but significantly (p < 0.05) better only in the second week

    PMID 20051111 · one of two readings recorded this

  • training alertness (week 2)

    increases, p = 0.05

    Training alertness was during every study week slightly better in the HICA group (3.6 ± 0.5; 4.2 ± 0.5; 4.1 ± 0.5; 4.3 ± 0.6) compared to the PLACEBO group (3.3 ± 0.6; 3.0 ± 0.9; 3.4 ± 1.1; 3.4 ± 0.8) but significantly (p < 0.05) better only in the second week

    PMID 20051111 · one of two readings recorded this

  • training alertness (week 3)

    no effect

    Training alertness was during every study week slightly better in the HICA group (3.6 ± 0.5; 4.2 ± 0.5; 4.1 ± 0.5; 4.3 ± 0.6) compared to the PLACEBO group (3.3 ± 0.6; 3.0 ± 0.9; 3.4 ± 1.1; 3.4 ± 0.8) but significantly (p < 0.05) better only in the second week

    PMID 20051111 · one of two readings recorded this

  • training alertness (week 4)

    no effect

    Training alertness was during every study week slightly better in the HICA group (3.6 ± 0.5; 4.2 ± 0.5; 4.1 ± 0.5; 4.3 ± 0.6) compared to the PLACEBO group (3.3 ± 0.6; 3.0 ± 0.9; 3.4 ± 1.1; 3.4 ± 0.8) but significantly (p < 0.05) better only in the second week

    PMID 20051111 · one of two readings recorded this

  • whole body DOMS

    no effect

    all weeks 1.5 ± 0.3 for HICA and 1.7 ± 0.4 for PLACEBO

    PMID 20051111 · one of two readings recorded this

  • whole body DOMS

    decreases, p = 0.05

    The HICA supplementation decreased significantly (p < 0.05) the whole body DOMS symptoms only in the 4th week of the treatment (1.4 ± 0.3) when compared to placebo (1.8 ± 0.2)

    PMID 20051111 · one of two readings recorded this

  • whole lean body mass

    increases, p = 0.05

    LBM: before 62.2 ± 6.7 and after 62.5 ± 6.5 for HICA and before 62.2 ± 4.9 and after 62.2 ± 4.6 for PLACEBO; p < 0.05

    PMID 20051111 · one of two readings recorded this

  • all outcomes (between-group and time-group interaction)

    no effect

    No significant between-group or time-group interactions were observed

    PMID 30102677 · one of two readings recorded this

  • cortisol (time effect)

    modulates, p = 0.001

    Time-dependent changes were observed for muscle thickness (P < 0.001), one repetition maximum bench press and squat (P < 0.001), Wingate peak power (P = 0.02), countermovement jump height (P = 0.03), power (P = 0.006), creatine kinase, insulin-like growth factor-1, growth hormone, and cortisol (all P < 0.001)

    PMID 30102677 · one of two readings recorded this

  • countermovement jump height (time effect)

    modulates, p = 0.03

    Time-dependent changes were observed for muscle thickness (P < 0.001), one repetition maximum bench press and squat (P < 0.001), Wingate peak power (P = 0.02), countermovement jump height (P = 0.03), power (P = 0.006), creatine kinase, insulin-like growth factor-1, growth hormone, and cortisol (all P < 0.001)

    PMID 30102677 · one of two readings recorded this

  • creatine kinase (time effect)

    modulates, p = 0.001

    Time-dependent changes were observed for muscle thickness (P < 0.001), one repetition maximum bench press and squat (P < 0.001), Wingate peak power (P = 0.02), countermovement jump height (P = 0.03), power (P = 0.006), creatine kinase, insulin-like growth factor-1, growth hormone, and cortisol (all P < 0.001)

    PMID 30102677 · one of two readings recorded this

  • ergogenic effect on any outcome variable

    no effect

    No leucine metabolite resulted in any ergogenic effects on any outcome variable

    PMID 30102677 · one of two readings recorded this

  • fat-free mass at baseline

    α-HICA (n = 10, fat-free mass [FFM] = 62.0 ± 7.1 kg)

    PMID 30102677 · one of two readings recorded this

  • fat-free mass at baseline

    HMB-Ca (n = 9, FFM = 65.6 ± 10.1 kg)

    PMID 30102677 · one of two readings recorded this

  • fat-free mass at baseline

    HMB-FA (n = 11, FFM = 62.7 ± 10.5 kg)

    PMID 30102677 · one of two readings recorded this

  • fat-free mass at baseline

    placebo (PLA; n = 10, FFM = 64.2 ± 5.7 kg)

    PMID 30102677 · one of two readings recorded this

  • growth hormone (time effect)

    modulates, p = 0.001

    Time-dependent changes were observed for muscle thickness (P < 0.001), one repetition maximum bench press and squat (P < 0.001), Wingate peak power (P = 0.02), countermovement jump height (P = 0.03), power (P = 0.006), creatine kinase, insulin-like growth factor-1, growth hormone, and cortisol (all P < 0.001)

    PMID 30102677 · one of two readings recorded this

  • insulin-like growth factor-1 (time effect)

    modulates, p = 0.001

    Time-dependent changes were observed for muscle thickness (P < 0.001), one repetition maximum bench press and squat (P < 0.001), Wingate peak power (P = 0.02), countermovement jump height (P = 0.03), power (P = 0.006), creatine kinase, insulin-like growth factor-1, growth hormone, and cortisol (all P < 0.001)

    PMID 30102677 · one of two readings recorded this

  • muscle thickness by ultrasound; one repetition maximum bench press and squat; Wingate peak power; countermovement jump height; creatine kinase, IGF-1, growth hormone, cortisol, total testosterone

    no effect, no significant between-group or time-group interactions

    Not recorded as a finding: the supporting sentence never names the compound

    No significant between-group or time-group interactions were observed.

    PMID 30102677 · one of two readings recorded this

  • muscle thickness (time effect)

    increases, p = 0.001

    Time-dependent changes were observed for muscle thickness (P < 0.001), one repetition maximum bench press and squat (P < 0.001), Wingate peak power (P = 0.02), countermovement jump height (P = 0.03), power (P = 0.006), creatine kinase, insulin-like growth factor-1, growth hormone, and cortisol (all P < 0.001)

    PMID 30102677 · one of two readings recorded this

  • one repetition maximum bench press and squat (time effect)

    increases, p = 0.001

    Time-dependent changes were observed for muscle thickness (P < 0.001), one repetition maximum bench press and squat (P < 0.001), Wingate peak power (P = 0.02), countermovement jump height (P = 0.03), power (P = 0.006), creatine kinase, insulin-like growth factor-1, growth hormone, and cortisol (all P < 0.001)

    PMID 30102677 · one of two readings recorded this

  • power (time effect)

    modulates, p = 0.006

    Time-dependent changes were observed for muscle thickness (P < 0.001), one repetition maximum bench press and squat (P < 0.001), Wingate peak power (P = 0.02), countermovement jump height (P = 0.03), power (P = 0.006), creatine kinase, insulin-like growth factor-1, growth hormone, and cortisol (all P < 0.001)

    PMID 30102677 · one of two readings recorded this

  • Wingate peak power (time effect)

    modulates, p = 0.02

    Time-dependent changes were observed for muscle thickness (P < 0.001), one repetition maximum bench press and squat (P < 0.001), Wingate peak power (P = 0.02), countermovement jump height (P = 0.03), power (P = 0.006), creatine kinase, insulin-like growth factor-1, growth hormone, and cortisol (all P < 0.001)

    PMID 30102677 · one of two readings recorded this

  • Body composition (DXA and BIS total body water)

    no effect

    No statistically significant between-group or group-by-time interactions were observed

    PMID 30588860 · one of two readings recorded this

  • Fat-free mass

    n = 40

    α-HICA (n = 10, fat-free mass [FFM] = 62.0 ± 7.1 kg), HMB-FA (n = 11, FFM = 62.7 ± 10.5 kg), HMB-Ca (n = 9, FFM = 65.6 ± 10.1 kg) or placebo (PLA; n = 10, FFM = 64.2 ± 5.7 kg)

    PMID 30588860 · one of two readings recorded this

  • Trunk fat-free mass

    increases, p = 0.05

    Time-dependent changes were observed for increase in trunk FFM (p < 0.05)

    PMID 30588860 · one of two readings recorded this

  • 1RM back squat change

    no effect

    back squat: α-HICA, 18.5% ± 18.9%; HMB-FA, 23.2% ± 16%; HMB-Ca, 10.5% ± 13.8%; PLA, 19.7% ± 9%

    PMID 31079555 · one of two readings recorded this

  • 1RM bench press change

    no effect, p = 0.001

    bench press: α-HICA, 13.8% ± 19.1%; HMB-FA, 15.5% ± 9.3%; HMB-Ca, 10% ± 10.4%; PLA, 14.4 ± 11.3%, both p < 0.001

    PMID 31079555 · one of two readings recorded this

  • all outcomes (between-group comparison)

    no effect

    No differences were found between groups at any time point

    PMID 31079555 · one of two readings recorded this

  • association of circulating inflammatory markers with change in outcomes

    no effect

    backwards elimination regressions showed that no circulating inflammatory marker consistently shared variance with the change in any outcome

    PMID 31079555 · one of two readings recorded this

  • fat-free mass at baseline

    α-hydroxyisocaproic acid group ([α-HICA], n = 10, Fat-free mass [FFM] = 62.0 ± 7.1 kg)

    PMID 31079555 · one of two readings recorded this

  • fat-free mass at baseline

    calcium β-hydroxy-β-methylbutyrate group ([HMB-Ca], n = 9, FFM = 65.6 ± 10.1 kg)

    PMID 31079555 · one of two readings recorded this

  • fat-free mass at baseline

    β-hydroxy-β-methylbutyrate free acid group ([HMB-FA], n = 11, FFM = 62.7 ± 10.5 kg)

    PMID 31079555 · one of two readings recorded this

  • fat-free mass at baseline

    placebo group ([PLA]; n = 10, FFM = 64.2 ± 5.7 kg)

    PMID 31079555 · one of two readings recorded this

  • high-sensitivity C-reactive protein (time effect)

    increases, p = 0.001

    IL-6, hsCRP (both p < 0.001) and TNF-α (p = 0.045)

    PMID 31079555 · one of two readings recorded this

  • interleukin-6, high-sensitivity C-reactive protein and tumour necrosis factor alpha, assessed at baseline and weeks 4 and 8

    no effect, no differences between groups at any time point

    Not recorded as a finding: the supporting sentence never names the compound

    No differences were found between groups at any time point.

    PMID 31079555 · one of two readings recorded this

  • interleukin-6 (time effect)

    increases, p = 0.001

    IL-6, hsCRP (both p < 0.001) and TNF-α (p = 0.045)

    PMID 31079555 · one of two readings recorded this

  • muscle thickness, rectus femoris (time effect)

    increases, p = 0.018

    Time-dependent increases were detected from baseline to week 8 for MT (vastus lateralis: p = 0.009; rectus femoris: p = 0.018)

    PMID 31079555 · one of two readings recorded this

  • muscle thickness, vastus lateralis (time effect)

    increases, p = 0.009

    Time-dependent increases were detected from baseline to week 8 for MT (vastus lateralis: p = 0.009; rectus femoris: p = 0.018)

    PMID 31079555 · one of two readings recorded this

  • training-induced inflammation (IL-6, hsCRP, TNF-α)

    no effect

    No leucine metabolite attenuated inflammation during training

    PMID 31079555 · one of two readings recorded this

  • tumour necrosis factor alpha (time effect)

    increases, p = 0.045

    IL-6, hsCRP (both p < 0.001) and TNF-α (p = 0.045)

    PMID 31079555 · one of two readings recorded this

  • 1-repetition maximum for back squat and bench press; phase angle and bioimpedance vector analysis patterns; fat-free mass and fat mass by DXA

    no effect, no group by time interactions

    Not recorded as a finding: the supporting sentence never names the compound

    Leucine metabolites have no effect on PhA, BIVA patterns or strength during an 8-week resistance training program, in resistance trained subjects.

    PMID 33337947 · one of two readings recorded this

  • 1RM back squat (time effect)

    increases

    time-dependent increases were observed for 1RM back squat and 1RM bench press

    PMID 33337947 · one of two readings recorded this

  • 1RM bench press (time effect)

    increases

    time-dependent increases were observed for 1RM back squat and 1RM bench press

    PMID 33337947 · one of two readings recorded this

  • association of phase angle with 1RM bench press change

    increases

    A direct association was observed between PhA and 1RM bench press changes (whole sample)

    PMID 33337947 · one of two readings recorded this

  • phase angle and bioimpedance vector (time course)

    no effect

    PhA and vector did not change over the training period

    PMID 33337947 · one of two readings recorded this

  • phase angle, BIVA patterns and strength (leucine metabolite effect)

    no effect

    Leucine metabolites have no effect on PhA, BIVA patterns or strength during an 8-week resistance training program, in resistance trained subjects

    PMID 33337947 · one of two readings recorded this

  • phase angle (group by time interaction)

    no effect

    No statistically group by time interactions were found, even adjusting for age

    PMID 33337947 · one of two readings recorded this